Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences

TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions, today announced its participation in the following investor conferences in March:

H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021 at 7:00 am (Eastern Time) a pre-recorded company presentation will become available for on-demand viewing.
Roth Capital Partners Annual Conference, Live fireside chat on Monday, March 15, 2021, at 9:00 am (Eastern Time).
Oppenheimer & Co. 31st Annual Healthcare Conference, Company presentation on Tuesday, March 16, 2021 at 9:20 am (Eastern Time).
Maxim Group Emerging Growth Virtual Conference on Wednesday, March 17, 2021 at 10:00 am (Eastern Time) a pre-recorded company presentation will become available for on-demand viewing.

A link to the webcast of each event will be available on the News and Events section of the Company’s website at antibethera.com. Following the events, a replay of the webcasts will be available on the website for 90 days.

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. Antibe’s current pipeline includes three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-safe alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005297/en/

Antibe Therapeutics Inc.
Christina Cameron
VP Investor Relations
+1 416-922-3460
[email protected]

Stern Investor Relations
Courtney Turiano
+1 212-362-1200
[email protected]

Source: Antibe Therapeutics Inc.

You May Also Be Interested In

• TiVo OS Unveils Major Platform Enhancements at IFA 2026, Expanding AI-Powered Discovery, Free Streaming, Live Sports and Interactive TV Experiences
• Baya Systems Chooses AdoreSys as Partner to Expand Semiconductor IP Availability Across China and Asia-Pacific
• ADA Price Prediction Hits a Wall at $0.19 While Pepeto Presale Wallets Load for Listing Day